FDA's FAERS E2B(R3) Upgrade Signals Shift for ICSR Submissions

FDA has laid the groundwork for a significant overhaul of electronic adverse event reporting through a series of public meetings focused on upgrading the FDA Adverse Event Reporting System (FAERS) to ICH E2B(R3) standards. For regulatory affairs and pharmacovigilance teams at pharmaceutical and biologics manufacturers, the transition will require systematic upgrades to Individual Case Safety Report (ICSR) submission infrastructure, revised business rules, and alignment with updated technical specifications. The shift touches both premarket and postmarket safety surveillance programs managed by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), meaning the scope extends across the product lifecycle.

The agency organized two public meetings in 2023, held on April 4 and November 7, building on earlier sessions in March 2019, July 2019, and February 2020. These meetings provided the pharmaceutical industry and other interested parties with updated information on plans, progress, and technical specifications for the electronic submission standards upgrade. FDA released draft documents during the 2020 meeting cycle, including FDA E2B(R3) Core Data Elements and Business Rules ver. 2.00 and FDA E2B(R3) Forward Compatible Rules, both in draft form. These documents represent the technical foundation that pharmacovigilance systems will need to incorporate. Presentation slides and agendas from all five meetings, along with full transcripts, remain available through FDA's public docket.

The progression from 2019 through 2023 reflects a deliberate, phased approach by FDA. The initial 2019 meetings introduced the agency's intent and early technical frameworks. The February 2020 session delivered the first draft business rules and forward-compatible rules. The 2023 meetings then provided updated information on the status of the transition. For plant-level and corporate quality teams operating under 21 CFR Part 211 and ICH Q10 quality management principles, the E2B(R3) migration is not merely an IT project. It carries direct implications for how safety data flows from manufacturing sites through to regulatory submissions, and any gaps in system readiness could affect compliance with postmarket reporting obligations.

Regulatory affairs leads should note that FDA accepted public comments within 30 days of each meeting, per the Federal Register Notices published for both the 2019/2020 and 2023 meeting series. While registration for all sessions is now closed, the agency has made video recordings of the April 4 and November 7, 2023 meetings available for one year from their respective dates, and transcripts for all five meetings are accessible at Regulations.gov. The contact point for questions related to the FAERS electronic submission upgrade is eprompt@fda.hhs.gov.

Pharmacovigilance and regulatory teams that have not yet begun mapping their current E2B(R2) submission workflows against the draft E2B(R3) core data elements and business rules should treat the available meeting materials as a primary reference. The draft documents released in 2020, combined with the 2023 updates, outline the expected data element structure and validation logic. Organizations submitting ICSRs to FAERS, whether for drugs or biologics, will need to confirm that their safety database vendors can support the R3 format, validate internal data mapping, and establish testing protocols ahead of any mandatory cutover date that FDA may announce. The agency's sustained engagement through five public meetings over four years signals that the transition timeline is advancing, and preparedness now will reduce compliance risk later.